Clinical trials: Immunity to Influenza Vaccine
Influenza
Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population
The study is designed to demonstrate a meaningful difference in immunogenicity between the candidate adjuvanted vaccine compared to the licensed Fluarix vaccine in subjects aged 50 years and above.
- Trial name
- NCT00377585
- Testing
- Fluarix, adjuvanted influenza vaccine
- Where
- 30 sites in United States, Belgium and 2 more
- Volunteers
- 3,350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
- Trial name
- NCT00735475
- Testing
- CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®)
- Where
- 13 sites in United States
- Volunteers
- 1,268 people, healthy volunteers welcome
- Sponsor
- Seqirus
2009 H1N1 Influenza
Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children
A total of 51 children between the ages of 4 and 9 will be randomized to receive a two dose schedule of either licensed live attenuated A/California/07/09 influenza vaccine (LAIV) or licensed inactivated A/California/07/09…
- Trial name
- H1N1Children (NCT01097941)
- Testing
- Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Rochester
END STAGE RENAL DISEASE
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
The purpose of this explorative trial is to collect preliminary data on efficacy and safety of thymosin alpha 1 given at different doses as an adjuvant to egg-derived H1N1sw monovalent influenza vaccine in hemodialysis patients.
- Trial name
- NCT01031966
- Testing
- MF59 adjuvanted H1N1 influenza monovalent vaccine, Thymosin alpha 1
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Influenza, Virus Diseases
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine
In the 20th century, influenza pandemics occurred in 1918, 1957, and 1968, and were associated with significant morbidity and mortality.
- Trial name
- NCT00734175
- Testing
- H6N1 Teal HK 97/AA ca recombinant vaccine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dietary Intervention
Probiotic, Prebiotic and Synbiotic Effect on Immunity
The aim of the study is to investigate the effect of dietary supplements such as probiotic, prebiotic and synbiotic on the immune response to influenza vaccination and faecal microbiota in adult healthy volunteers.
- Trial name
- NCT01084434
- Testing
- probiotic, prebiotic, Synbiotic
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Reading
Healthy Volunteer
Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
Background: Vaccines help prevent disease by causing the body to have an immune response. Many parts of this response happen in the blood. This response happens over days and weeks after getting the vaccine.
- Trial name
- NCT04025580
- Testing
- Flucelvax, Fluvirin, Fluzone High Dose
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
This study will examine the immune responses to the seasonal influenza vaccine in single cells of the nasal passages when compared with cells in circulating blood.
- Trial name
- NCT03023553
- Testing
- Fluzone®, FluMist®
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Stanford University
Immunity to Influenza Vaccine
Cell Mediated Immunity in Older Adults
This study is to study the immune response to the flu vaccine in people 65 years old and older. Only adults 65 years old and older and who are getting their flu vaccine are being asked to join in this study.
- Trial name
- CMI (NCT01189123)
- Testing
- High dose influenza vaccine Sanofi-Pasteur, fluzone by sanofi pasteur
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Influenza
T and B Cell Response to Avian Flu Vaccine
The purpose of this substudy study is to evaluate the types of cells involved in fighting infection to the A/H5N1 (avian flu virus) vaccine.
- Trial name
- NCT00337896
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Influenza
Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults
This clinical fase IV study, using the administration of a single dose of a quadrivalent, inactivated, split influenza virus vaccine as biological intervention will mirror a study conducted at Imperial College, London, UK that…
- Trial name
- NCT03160118
- Testing
- Seasonal,quadrivalent,influenza vaccine
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Vaccine Refusal
Promoting Altruism to Enhance Vaccine Acceptance
Subjects enrolled in this study are eligible for the seasonal influenza vaccine. The purpose of this research study is to figure out if increasing individuals' awareness of the benefits of herd immunity, specifically to the local…
- Trial name
- NCT04568590
- Testing
- educational intervention
- Where
- United States
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Influenza
Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant
This study is designed to assess safety, tolerability and immunogenicity of Fluzone® vaccine with four dose levels of JVRS-100 adjuvant compared to Fluzone® vaccine alone in healthy adults 18-49 years of age.
- Trial name
- H-100-001 (NCT00662272)
- Testing
- Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine
- Where
- 2 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Colby Pharmaceutical Company
Safety Markers of Adjuvanted Influenza Vaccine
Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses
The purpose of this protocol is to generate a set of data that will be analysed by integrated systems biology approach, for validation in subsequent clinical trials or in animal models.
- Trial name
- NCT02523287
- Testing
- Fluad, Saline
- Where
- Belgium
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Normal Physiology
Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults
Background: One form of the influenza vaccine is a nasal spray. It uses a live but weakened flu virus. Researchers want to better under how the live vaccine interacts with the body s immune system.
- Trial name
- NCT01730144
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
B-cell Malignancies
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
The primary objective of this study is to assess the immune response to an influenza vaccine in adults with B-cell malignancies who are currently receiving treatment with idelalisib in a Gilead-sponsored study (parent study).
- Trial name
- NCT03701438
- Testing
- Influenza Vaccine
- Where
- 2 sites in Czechia, Spain
- Volunteers
- 2 people
- Sponsor
- Gilead Sciences
Influenza
Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005
The objectives of the study are to assess the immunogenicity and safety among three different lots of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
- Trial name
- NCT00161811
- Testing
- Vero Cell-derived Influenza Vaccine, Egg cell-derived Influenza Vaccine
- Where
- 4 sites in Austria, Germany
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
This Phase 2a clinical study is designed to evaluate the immunogenicity and the safety of one dose of OVX836 influenza vaccine administered IM, confirm the dose level and regimen, and expand immunogenicity and safety data to…
- Trial name
- NCT04192500
- Testing
- OVX836, Quadrivalent seasonal influenza vaccine (Influvac TetraTM)
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza A Virus, H7N9 Subtype
Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals
H7N9 viruses have caused a recent outbreak of severe illness in humans in China. The purpose of this study is to evaluate the safety and immune response of an H7N9 A/Anhui/13 ca influenza virus vaccine followed by an inactivated…
- Trial name
- NCT02151344
- Testing
- H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 vaccine
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03022422
- Testing
- TIV, High-Dose TIV
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Stanford University